WAM
MYGN icon

Wakefield Asset Management’s Myriad Genetics MYGN Stock Holding History

Wakefield Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,893
Closed -$375K – 235
2018
Q4 		$375K Buy
12,893
+5,684
+79% +$204K 0.16% 115
2018
Q3 		$332K Buy
+7,209
New +$321K 0.13% 94

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wakefield Asset Management's MYGN Position: Q1 2019 in Review

Wakefield Asset Management sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 12,893 shares — an estimated $375K sold.

Wakefield Asset Management first reported a position in MYGN in Q3 2018 and held it in 2 quarters. The position peaked at $375K in Q4 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

  • Wakefield Asset Management reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
  • Wakefield Asset Management sold 12,893 Myriad Genetics shares in Q1 2019, an estimated $375K.
  • Wakefield Asset Management first reported a position in Myriad Genetics in Q3 2018 and held it in 2 quarters.
  • Wakefield Asset Management's Myriad Genetics position peaked at $375K in Q4 2018.
  • 262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Wakefield Asset Management's 13F filing for Q1 2019, filed 6 May 2019.